First Trust Advisors
AVIR icon

First Trust Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

First Trust Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-203,566
Closed -$761K – 2354
2023
Q2 		$761K Buy
203,566
+1,781
+0.9% +$6.67K ﹤0.01% 2039
2023
Q1 		$676K Buy
201,785
+15,387
+8% +$62.4K ﹤0.01% 2060
2022
Q4 		$897K Sell
186,398
-12,881
-6% -$65.2K ﹤0.01% 1995
2022
Q3 		$1.13M Buy
+199,279
New +$1.53M ﹤0.01% 1945

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors's AVIR Position: Q3 2023 in Review

First Trust Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 203,566 shares — an estimated $761K sold.

First Trust Advisors first reported a position in AVIR in Q3 2022 and held it in 4 quarters. The position peaked at $1.13M in Q3 2022. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • First Trust Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • First Trust Advisors sold 203,566 Atea Pharmaceuticals shares in Q3 2023, an estimated $761K.
  • First Trust Advisors first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • First Trust Advisors's Atea Pharmaceuticals position peaked at $1.13M in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.